ALSO NOTED: MAP touts IIa data; Isis pockets $2M milestone;and much more...

> A surge of hopeful research reports on the potential of stem cells has helped fatten profits at Cryo-Save. The company says its stem cell storage work jumped 41 percent last year. Demand is particularly strong in Spain and Hungary. Report

> MAP Pharmaceuticals says that a Phase IIa trial demonstrated positive results for MAP0005, a combination of budesonide, a corticosteroid, and formoterol, a long-acting beta2-agonist. Release

> Isis Pharmaceuticals is pocketing a $2 million milestone payment on the announcement that Bristol-Myers Squibb Company has selected a compound from the companies' collaboration as a development candidate. Release

> Chelsea Therapeutics has licensed the global rights to Active Biotech AB's 1-3D compounds for autoimmune disease and transplant rejection. Release

> Sirion Therapeutics is touting data from late-stage studies of Durezol (difluprednate ophthalmic emulsion) 0.05% for postoperative ocular inflammation. Report

> Just about everybody agrees that the FDA needs a safety overhaul--including Commissioner Andrew von Eschenbach, who recently admitted the agency is in crisis. The agency itself drafted a five-year plan that would channel user fees into more safety evaluators, epidemiologists, regulatory project managers, and risk experts, all to beef up post-marketing drug-safety oversight. Report

> Should drugs be labeled with their country of origin? Report

> Europe is debating drug marketing--and the pharma industry is loudly protesting that it is not asking for the right to pursue DTC advertising. Report

And Finally... A case of human-to-human transmission of bird flu has been confirmed in China, but authorities say it is another instance where the spread of the disease has been limited to a close blood relative. In this case an experimental H5N1 vaccine demonstrated that it could possibly vanquish the lethal virus. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.